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A new tRNA, THG73, has been designed and evaluated
as a vehicle for incorporating unnatural amino acids
site-specifically into proteins expressed in vivo using
the stop codon suppression technique. The construct is
a modification of tRNAGln(CUA) from Tetrahymena ther-
mophila, which naturally recognizes the stop codon
UAG. Using electrophysiological studies of mutations at
several sites of the nicotinic acetylcholine receptor, it is
established that THG73 represents a major improve-
ment over previous nonsense suppressors both in terms
of efficiency and fidelity of unnatural amino acid incor-
poration. Compared with a previous tRNA used for in
vivo suppression, THG73 is as much as 100-fold less
likely to be acylated by endogenous synthetases of the
Xenopus oocyte. This effectively eliminates a major con-
cern of the in vivo suppression methodology, the unde-
sirable incorporation of natural amino acids at the sup-
pression site. In addition, THG73 is 4–10-fold more
efficient at incorporating unnatural amino acids in the
oocyte system. Taken together, these two advances
should greatly expand the range of applicability of the
in vivo nonsense suppression methodology.
Methods that facilitate the engineering of protein variants
are critical to studies of molecular recognition and protein
function. Initially, bacterial genetics provided the primary tool
for making amino acid substitutions in proteins. Because some
strains express a naturally occurring nonsense suppressor
tRNA having an altered anticodon, an amino acid could be
incorporated at specific sites in response to nonsense mutations
that created stop codons in messenger RNA (1–3). The utility of
the suppression approach was greatly increased once it became
possible to engineer nonsense-suppressing anticodons into
tRNAs, thereby allowing a broader range of amino acids to be
incorporated at the site of interest (4, 5). Subsequently, it was
shown that a nonsense suppressor tRNA could be aminoacyl-
ated using organic synthesis, allowing for the in vitro incorpo-
ration of unnatural amino acids into proteins in a site-directed
manner (6). Compared with conventional site-directed mu-
tagenesis, this methodology enabled a much broader range of
side chain modifications, including the incorporation of bio-
physical probes and cross-linking agents, as well as modifica-
tions to the protein main chain (7).
More recently, the unnatural amino acid methodology has
been extended to allow expression of modified proteins in intact
cells by direct injection of the mutated mRNA and the chemi-
cally acylated suppressing tRNA into Xenopus oocyte cells (see
Fig. 1) (8). A specific tRNA (MN3) was designed for use in vivo,
and it was found (8) to be an improvement over the tRNAPhe-
derived suppressor (6, 7) that had been used in previous in vitro
studies. Using MN3, unnatural amino acids related to Tyr were
inserted into the nicotinic acetylcholine receptor (nAChR)1 a
subunit at several natural Tyr sites known to be important in
agonist binding, and the results were evaluated using electro-
physiological measurements.
New results described here, however, establish that MN3
does not constitute an optimal solution to the in vivo suppres-
sion problem. As in previous studies, we have used the nAChR
(9–11) to evaluate nonsense suppression. This ion channel
protein is highly compatible with the heterologous expression
system of the Xenopus oocyte, has a number of well-studied
mutation sites for evaluation, and gives readily characterizable
electrophysiological responses to added agonist. By studying
positions in the nAChR a subunit that are more tolerant with
regard to substitution, we demonstrate that tRNA MN3 can
lead to incorporation of natural amino acids at the mutation
site along with the desired unnatural amino acid, probably
because the chemically acylated tRNAMN3 is being reacylated
(and/or edited) by synthetases that are endogenous to the Xe-
nopus oocyte. In addition, previous in vitro studies (8) of MN3
indicated that the absolute efficiency of unnatural amino acid
incorporation was low with this construct, and the in vivo
studies appeared to support this. While this low efficiency could
be compensated for in the initial studies mentioned above,
subsequent work to be described here and elsewhere estab-
lished that the apparent inefficiency of MN3 became a serious
handicap at other mutation sites or in efforts to incorporate
unnatural amino acids that differ in more substantial ways
from the natural set.
The present work thus addresses two related challenges
posed by the in vivo suppression method. 1) We sought to
design suppressor tRNAs that are more efficient at incorporat-
ing an unnatural amino acid at the site of interest in the
protein. 2) We sought to prevent or greatly reduce endogenous
tRNA synthetases from editing and/or reacylating the suppres-
sor tRNA, in order to prevent the inadvertent site-specific
incorporation of a natural amino acid into the target protein.
We have now designed a new nonsense suppressor tRNA
that can be used to deliver amino acids to more “promiscuous”
* This research was supported by National Institutes of Health
Grants NS11756 (to H. A. L.), NS34407 (to D. A. D.), and GM48560 (to
J. N. A.). The costs of publication of this article were defrayed in part by
the payment of page charges. This article must therefore be hereby
marked “advertisement” in accordance with 18 U.S.C. Section 1734
solely to indicate this fact.
‡ These authors contributed equally to this work.
¶ To whom correspondence should be addressed: Div. of Chemistry
and Chemical Engineering–164-30, California Institute of Technology,
Pasadena, CA 91125. Tel.: 818 395 6089; Fax: 818 564 9297; E-mail:
dad@igor.caltech.edu.
1 The abbreviations used are: nAChR, nicotinic acetylcholine recep-
tor; AChR, acetylcholine receptor; GlnRS, glutaminyl-tRNA synthetase;
LysRS, lysyl-tRNA synthetase; NVOC, nitroveratryloxycarbonyl.
THE JOURNAL OF BIOLOGICAL CHEMISTRY Vol. 271, No. 38, Issue of September 20, pp. 23169–23175, 1996
© 1996 by The American Society for Biochemistry and Molecular Biology, Inc. Printed in U.S.A.
23169
sites of nAChR and other proteins. The new design strategy
begins with a eukaryotic tRNA that is already competent to
translate UAG codons. In Tetrahymena thermophila and other
ciliates, the UAG codon does not signal the termination of
translation. Instead, it is translated as a glutamine by the
tRNAGln(CUA) isoacceptor, producing a deviation from the
“universal” genetic code (12). Evidently T. thermophila tRNA-
Gln(CUA) has evolved the necessary properties to efficiently
translate UAG codons in a variety of mRNA codon contexts.
Indeed, previous in vitro translation experiments showed that
when wheat germ (13) or rabbit reticulocyte (12) systems were
supplemented with a T. thermophila synthetase preparation,
tRNAGln(CUA) efficiently translated normal UAG stop codons
in a variety of heterologous mRNAs. Based on principles de-
rived from studies of translation efficiency and tRNA recogni-
tion, (14–16) we have modified T. thermophila tRNAGln(CUA)
to produce a new tRNA, THG73. The new tRNA satisfies both
requirements 1 and 2 above and has greatly expanded the range
of applicability of the nonsense suppression method (17, 18).
EXPERIMENTAL PROCEDURES
Materials—NVOC-protected dCA-amino acids were prepared accord-
ing to literature procedures (19). FokI restriction endonuclease and T4
RNA ligase were purchased from New England Biolabs. T7 RNA po-
lymerase was purified using the method of Grodberg and Dunn (20)
from the overproducing strain Escherichia coli BL21 harboring the
plasmid pAR1219 (21).
Gene Construction and RNA Preparation—The genes for the T. ther-
mophila tRNAGln(CUA) having either an A73 or G73 (THA73 and
THG73, respectively) and flanked by an upstream T7 RNA polymerase
promoter and a downstream FokI restriction site were constructed from
eight overlapping synthetic DNA oligonucleotides and cloned into
pUC19 giving the plasmids pTHA73 and pTHG73, respectively (see Fig.
2A). Template DNA for transcription of tRNA lacking the 39-terminal
C75 and A76 was prepared by digesting the plasmid DNA with FokI
restriction endonuclease. Our previous tRNA gene, pMN3, was con-
structed in a similar manner (8). In vitro transcription of the linearized
DNA template and purification of the truncated THA73 and THG73
RNA products were performed as described previously (22). MN3 tran-
script (lacking the 39-terminal C75 and A76) was prepared in the same
manner as above from FokI-linearized pMN3 (8). mRNA for the wild
type and mutants (codon UAG) of the mouse muscle a, b, g, and d
nAChR subunits were prepared by in vitro transcription of the appro-
priate linearized plasmid construct.
Ligation of dCA-Amino Acids to Suppressor tRNAs—The NVOC-
protected dCA-amino acids were coupled to the THA73, THG73, and
MN3 FokI runoff transcripts using T4 RNA ligase (Fig. 1) (23). Ligation
reaction mixtures contained 42 mM HEPES-KOH, pH 7.4, 10% Me2SO
(v/v), 4 mM dithiothreitol, 20 mM MgCl2, 0.2 mg/ml bovine serum albu-
min, 150 mM ATP, 10 mM tRNA transcript, 300 mM NVOC-protected
dCA-amino acid, and 2,000 units/ml of T4 RNA ligase. After incubation
at 37 °C for 2 h, the reaction mixtures were extracted once with an
equal volume of phenol:CHCl3:isoamyl alcohol (25:24:1, pH 4.5) and
once with an equal volume of CHCl3:isoamyl alcohol (24:1, pH 4.5),
precipitated with 2.5 volumes of ethanol at 220 °C, dried, resuspended
in 1 mM NaOAc (pH 4.5), and stored at 280 °C. The percentage of
ligated product as judged by electrophoresis on high resolution 8%
denaturing polyacrylamide gels was approximately 90% for the THA73
and MN3 transcripts and only 30% for the THG73 transcripts. The
reported quantities of all ligated tRNAs have been corrected for ligation
efficiency (30%).
Oocyte Microinjections and Electrophysiological Measurements—
Prior to microinjection, the ligated NVOC-aminoacyl-tRNA was rena-
tured by heating to 65 °C for 3 min in 1 mM NaOAc (pH 4.5). The NVOC
protecting group was subsequently removed by irradiating the sample
for 5 min with a 600-W xenon lamp equipped with WG-335 and UG-11
filters (Schott). The desired amounts of deprotected aminoacyl-tRNA
and a, b, g, and d mRNAs were then mixed and immediately microin-
jected (50 nl) into Xenopus oocytes using published methods (24).
Electrophysiological measurements were carried out 18–30 h after
injection using a two-electrode voltage clamp circuit. Oocytes were
bathed in solutions containing 5 mM HEPES-NaOH (pH 7.4), 96 mM
NaCl, 2 mM KCl, 1 mM MgCl2, and 1 mM atropine. Macroscopic ACh-
induced currents were recorded in response to bath application 200–
800 mM ACh at a holding potential of 280 mV. All numerical and plotted
data are from measurements obtained for four to eight individual oo-
cytes and are reported as the mean 6 S.E.
RESULTS
Suppressor Design—Several factors must be considered in
designing a new tRNA to meet the goals stated above. Trans-
lation efficiency depends not only on anticodon-codon base pair-
ing, but also on other tRNA structural characteristics, includ-
ing the sequence of the anticodon stem and loop (25) and the
D-stem (26). In addition, post-transcriptional modification
of nucleotides throughout the tRNA can affect translation
efficiency (27).
Goal 1 requires a tRNA that can translate UAG codons with
increased efficiency. Although the optimal anticodon stem/loop
context for a CUA anticodon has been established for the E. coli
translation system (25), the corresponding rules for eukaryotes
have not been determined. We therefore chose to begin with T.
thermophila tRNAGln(CUA), which naturally recognizes the
UAG codon and efficiently suppresses UAG in vitro (12, 13).
Goal 2 requires a suppressor that cannot be recognized by
the Xenopus aminoacyl-tRNA synthetases and therefore has a
“null” in vivo amino acid identity. Biochemical studies (28, 29)
and x-ray diffraction analyses (30, 31) indicate that E. coli
glutaminyl-tRNA synthetase (GlnRS) recognizes the first three
base pairs of the acceptor stem, the anticodon nucleotides
FIG. 1. Scheme for incorporating unnatural amino acids into
proteins expressed in Xenopus oocytes.
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(Py34, U35, and G36), and a hairpin structure formed by RNA-
RNA interactions between N73 and the phosphorus oxygen at
position 72 of E. coli glutamine tRNAs. Eukaryotic GlnRS
probably recognizes nucleotides in these regions as well. The
G36A mutation in T. thermophila tRNAGln(CUA) that endows
it with its distinctive codon coupling capacity is unlikely to
affect aminoacylation by the cognate T. thermophila GlnRS but
would be expected to reduce aminoacylation by other eukary-
otic GlnRS. In support of these ideas, in vitro aminoacylation
determinations showed that native T. thermophila tRNAGln-
(CUA) was efficiently aminoacylated by T. thermophila GlnRS
but was not a substrate for wheat germ (13) or rabbit (12)
GlnRS.
Thus, we investigated T. thermophila tRNAGln(CUA), antic-
ipating that it might show both high translational efficiency
and a potentially “null” amino acid identity in Xenopus oocytes.
As a further precaution against recognition by Xenopus GlnRS,
we constructed two mutants, U73A and U73G (Fig. 2B), which
have been termed THA73 and THG73, respectively. These
changes alter the wild type U73 that is likely to be recognized
by eukaryotic GlnRS. These changes also facilitated the liga-
tion of the 39-terminal dCA to the T7 transcripts of tRNAGln-
(CUA) (see “Experimental Procedures”), because a pyrimidine
was replaced by a more favorable purine at the position adja-
cent to the ligation junction (32).
Suppressor Evaluation—In these studies, an amino acid was
chemically (rather than enzymatically) esterified to the 39 OH
of the dinucleotide dCA to form, for instance, dCA-Tyr (Fig. 1).
Either dCA alone or aminoacylated dCA was then enzymati-
cally coupled to the 39 C74 of the tRNA to form either a full-
length but unacylated tRNA (such as THG73-dCA), or a full-
length chemically charged aminoacyl-tRNA (such as THG73-
dCA-Tyr) (Fig. 1). Either of these full-length tRNAs was
injected into oocytes along with nAChR mRNA. The response
for oocytes injected with full-length, chemically acylated tRNA
can be due to the insertion of the chemically acylated amino
acid (the desired outcome) but also to the undesired insertion of
amino acids that were coupled to the tRNA by the endogenous
synthetases through either an editing mechanism or reacyla-
tion. The signal from oocytes injected with unacylated (dCA)
suppressors can be used to estimate the extent of this endoge-
nous acylation reaction, leading to the ratio Ruaa 5 ItRNA-dCA-Tyr/
ItRNA-dCA as an index of unnatural amino acid incorporation.
Ruaa is a measure of the operational suppression efficiency.
Additional data of relevance to the efficiency question are
provided by currents measured after injection of mRNA only.
This experiment tests for read-through by the endogenous Xe-
nopus translation system and generally produces small cur-
rents that vary among oocyte batches (see below).
Throughout this work we will use our suppressor tRNAs to
deliver amino acids that are, in fact, natural, either Tyr or Leu.
This is the most appropriate way to evaluate the tRNAs, re-
moving any complications that might be introduced by the
unnatural amino acid. However, we have previously shown
that MN3 can deliver unnatural amino acids (8), and we have
also found that THG73 is fully competent to deliver unnatural
amino acids in a variety of contexts (17, 18).
Operational Suppression Efficiency—For studies of the com-
parative efficiencies of suppressor tRNAs, we focused on the
a180 site of the nAChR. Fig. 3 compares currents obtained
when oocytes were coinjected with a180UAG mRNA and with
varying amounts of either the MN3 or the THG73 suppressor
tRNAs. Observed currents reached 50% of Imax when less than
0.5 ng of THG73-dCA-Tyr was injected per oocyte. We find that
2–3-fold more MN3-dCA-Tyr was required to obtain the same
relative signal, a small but likely significant effect.
From a practical viewpoint, the issue is not solely the
amount of nAChR observed but rather the extent to which the
suppression methodology gives current levels above those seen
from controls involving tRNA-dCA (evaluating reacylation and
editing) and injection of mRNA only (evaluating endogenous
read-through). When this operational suppressor efficiency, ex-
pressed as Ruaa, is high, appropriate quantities of injected
tRNA and mRNA will produce currents that can be confidently
FIG. 2. Design of the engineered T. thermophila tRNAGln CUA
suppressor genes for in vitro transcription with T7 RNA polym-
erase. A, the DNA sequence for the suppressor tRNA gene, the up-
stream T7 promoter, and downstream run-off restriction endonuclease
sites are given. The tRNA gene sequence is based on the published T.
thermophila tRNAGln RNA sequence (12). The recognition and corre-
sponding cleavage site for the 39-terminal FokI restriction enzyme is
indicated by boldface letters and associated arrows. B, nucleotide se-
quence for the THA73 and THG73 RNAs obtained from run-off tran-
scription of FokI-linearized DNA.
FIG. 3. Concentration dependence of acylated (dCA-Tyr) and
unacylated (dCA) forms of MN3 and THG73 suppressor tRNAs
on the ACh-induced currents at position a180. Oocytes were coin-
jected with a nAChR a180UAG:b:g:d mRNA concentration ratio of
100:1:1:1 (16 ng of total mRNA) and the indicated amount of acylated or
unacylated tRNA. Currents were recorded at 200 mM ACh. The mean
%Imax for each tRNA concentration was calculated by setting 100% at
the highest mean current obtained for the acylated form of each sup-
pressor tRNA (6.3 ng for MN3 and 4.2 ng THG73). The injected tRNA
species are designated as follows: MN3-dCA (E), MN3-dCA-Tyr (l),
THG73-dCA (M), THG73-dCA-Tyr (f).
In Vivo Nonsense Suppression Using an Engineered tRNA 23171
attributed to receptor that has incorporated the desired unnat-
ural amino acid. As shown in Fig. 3, significant currents were
seen on injection of MN3-dCA, and current levels increased as
the amount of injected MN3-dCA increased. In striking con-
trast, little or no current was measured for all tested concen-
trations of THG73-dCA (Fig. 3), indicating that MN3-dCA but
not THG73-dCA was being acylated by an endogenous synthe-
tase. Consequently, the operational efficiency (Ruaa) was as
much as 100-fold higher for THG73 than for MN3 in this
experiment (Fig. 3).
The muscle nAChR is composed of five subunits with the
stoichiometry a2bgd (9–11). In our original experiments (8), the
limiting factor for detectable signals was suppression of the
UAG codon in a subunit mRNA by MN3, which was estimated
to occur with only 10% efficiency in vitro. We therefore micro-
injected oocytes with a large excess of mRNA for a subunit
variants to give a final subunit mRNA ratio of 100:1:1:1 (a:b:
g:d). To assess whether the improved efficiency of THG73 in
vivo could eliminate the need for this unusual subunit mRNA
ratio, we measured the current that was obtained using a
comparatively small amount of coinjected tRNA and varying
amounts of the a180UAG mRNA subunit.
When the mRNA subunit ratio was 100:1:1:1 (16 ng of total
mRNA), MN3-dCA-Tyr and THG73-dCA-Tyr gave comparable
signals: 5000 6 760 and 5200 6 760 nA of current, respectively.
However, when we dropped the subunit ratio to 4:1:1:1 (1.1 ng
of total mRNA), MN3-dCA-Tyr and THG73-dCA-Tyr gave
530 6 130 and 2200 6 250 nA of current, respectively, estab-
lishing that only THG73 is able to produce large quantities of
protein at the more conventional, 4:1:1:1 subunit ratio. These
data again indicate that THG73 is a more efficient suppressor
than MN3.
MN3 and THG73 were compared further at five positions in
the nAChR subunits that have somewhat different codon con-
texts (Fig. 4A). Fig. 4B shows that the current due to UAG
suppression at the five test positions ranged between 3 and 8
mA when THG73 was injected and that, in all cases, the current
was at least 5-fold greater than that obtained for MN3. This
result again indicates that THG73 is operationally a more
efficient suppressor than is MN3 in vivo.
Acylation by the Endogenous Synthetases—To test for acyla-
tion of suppressor tRNA by an endogenous Xenopus synthetase,
we studied oocytes co-injected with nAChR mRNA having a
UAG mutation at several positions. Studies of the highly con-
served position a198 (wild type 5 Tyr) indicate that aromatic
amino acids are strongly preferred at this position (33). On the
other hand, position a180 is not highly conserved when one
considers both muscle and neuronal nAChR a subunits. That
is, a180 is less restricted by amino acid type than a198. This
suggests that a180 is the better site to seek evidence for re-
acylation of the tRNA, since the likelihood is greater that
incorporation of a natural amino acid will still produce a func-
tional (and hence detectable) receptor.
The operational suppression efficiency ratio Ruaa at position
a198 was larger than 250 for all three engineered suppressor
tRNAs (Table I). When evaluated at the more promiscuous
position a180, however, Ruaa was 100 for THG73 but was less
than 2 for both MN3 and THA73. This high ratio for THG73 is
primarily due to the fact that oocytes injected with THG73-dCA
had low currents, suggesting that THG73 is a much poorer
substrate for endogenous synthetases. Thus, although THA73
and MN3 are adequate tRNAs for inserting unnatural amino
acids at a highly restricted position like a198, THG73 is more
versatile, since it functions properly at a more permissive site.
The highly conserved position termed Leu99 in the M2 region
of all nAChR subunits presented a particularly sensitive test
for acylation by endogenous synthetases or read-through by
endogenous tRNAs, because many mutations at this position
actually increase ACh sensitivity (34–36). Fig. 5A shows that
when MN3 is the vehicle for incorporation of leucine at the
99-position of the b subunit (b262) the dose-response relation
FIG. 4. ACh-induced currents at five nAChR positions using
acylated MN3 and acylated THG73 suppressor tRNAs. A, codon
contexts; B, observed currents. Oocytes were injected with 1.25 ng of
tRNA dCA-Tyr for determinations at positions a198 and a93 and 1.25
ng tRNA dCA-Leu at positions b262, g260, and d265. Total injected
amounts and concentration ratios (a:b:g:d) of nAChR subunit mRNAs
for each test were as follows: a93UAG and a198UAG, 1.1 ng, 4:1:1:1;
b262UAG, g260UAG, and d265UAG mRNA, 0.25 ng, 2:1:1:1. Currents
were recorded at 400 mM ACh. Shaded and open boxes are for acylated
MN3 and THG73, respectively.
TABLE I
ACh-induced current ratios (Ruaa) for the MN3, THA73, and THG73
suppressor tRNAs determined at two nAChR a subunit positions, 180
and 198, containing a UAG codon
Oocytes were coinjected with 12.5 ng (MN3 and THA73) or 4.2 ng
(THG73) of acylated or unacylated tRNA and nAChR a180UAG or
a198UG mRNA plus b, g, and d mRNA at a concentration ratio of
100:1:1:1 (16.1 ng of total mRNA). Current was recorded at 800 mM ACh.
Oocytes injected with nAChR a180UAG mRNA only or nAChR
a198UAG mRNA only (no tRNA) gave mean currents of 9 6 3 nA or no
detectable current, respectively.
UAG
position
Suppressor
tRNA
Mean current 6 S.E. (nA) Ruaa
(dCA-Tyr/dCA)dCA dCA-Tyr
a198 MN3 3 6 1 2950 6 550 980
THA73 13 6 5 3640 6 680 280
THG73 4 6 0.4 2720 6 220 680
a180 MN3 3390 6 1050 5460 6 770 1.6
THA73 4210 6 380 7680 6 950 1.8
THG73 47 6 23 4800 6 870 100
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deviates substantially from wild type at low concentrations of
ACh. This indicates the presence of a small number of receptors
having an EC50 less than wild type, revealing the incorporation
of an unintended residue at this position. Further experiments
(not shown) establish that the low EC50 component can become
quite pronounced under different conditions with MN3. In clear
contrast, when THG73 is used, the resulting dose-response
curve superimposes on that for wild type, with no detectable
low EC50 component (Fig. 5A). This is a very sensitive indica-
tion that suppression has proceeded with minimal reacylation
when THG73 is used.
The sensitive measurements based on position 99 do reveal a
detectable signal with injection of the b262UAG mRNA but no
tRNA of any type. This reflects a slight amount of read-through
of UAG codons by tRNAs inherent to the Xenopus translation
system. Importantly, this signal is not increased by coinjection
of THG73-dCA (Fig. 5B). Thus, the lower end of the detection
limit of suppression using THG73 is determined not by re-
acylation mechanisms, but rather by the read-through effi-
ciency of the Xenopus system. Signals such as those in Fig. 5B
are too small for systematic dose-response studies that might
determine the tRNA responsible for the read-through. We em-
phasize, however, that this level of read-through represents
less than 1% of our typical signal in a successful suppression
experiment and therefore does not constitute a limiting factor
at present.
DISCUSSION
The development of methods for controlled incorporation of
unnatural amino acids greatly expands the range of structure/
function studies available for complex proteins. To apply these
methods to integral membrane proteins such as receptors,
channels, and transporters, we previously adapted the non-
sense suppressor/chemical acylation approach to the heterolo-
gous expression system of the intact Xenopus oocyte (8). This
allows for site-specific, atomic scale modifications of proteins
that can be studied in intact cells. A major challenge in devel-
oping this approach was to design a suppressor tRNA that
efficiently translates UAG codons yet is not a substrate for any
of the endogenous Xenopus synthetases. The present measure-
ments unambiguously show that THG73 represents a signifi-
cant improvement over our original suppressor MN3 with re-
gard to both operational suppression efficiency and resistance
to reacylation, greatly expanding the potential range of appli-
cability of this methodology. In addition, the present work
represents the first use of the nonstandard genetic code of
ciliates for protein engineering in intact cells.
Efficiency of Suppression—The present study assesses the
suppression efficiency of our engineered tRNAs by comparing
the signals obtained from nAChR using the chemically acylated
versus nonacylated versions of each tRNA. According to this
criterion, THG73 is a more efficient suppressor than is MN3.
However, it is difficult to precisely identify the major factors
responsible for this improved efficiency. The nAChR possesses
an a2bgd quaternary structure and is an integral membrane
protein, so the production of functional receptors depends on
many other factors besides suppression efficiency, such as post-
translational receptor assembly and membrane localization
steps. Also, both the sequences of MN3 and THG73 as well as
the presence or absence of an amino acid are likely to affect
interactions with the large multienzyme complexes that medi-
ate eukaryotic protein synthesis (37, 38) and entry into the
tRNA degradation pathway (39). Our experiments do not di-
rectly address these issues.
We contend, however, that chemically acylated THG73 is
fairly efficient. Because the level of functional receptors in-
creases with the injected tRNA concentration and reaches sat-
uration, the injected THG73must be effectively competing with
the endogenous tRNAs. Moreover, the lowest concentration of
injected THG73 roughly equals that of any individual endoge-
nous tRNA isoaccepting species (40). It seems unlikely that the
improved efficiency of THG73 relative to MN3 is due to differ-
ential stabilities of the tRNAzEF-1azGTP ternary complexes,
since EF1-a is present in relatively high concentrations in the
oocyte (41) and should not be limiting. Rather, it is more likely
that THG73 either interacts more productively with the UAG
codon on the ribosome or competes more effectively with re-
lease factor than does MN3.
THG73 is derived from an in vitro transcription reaction and
therefore possesses no modified nucleotides when injected. Se-
quence comparisons for a wide variety of eukaryotic tRNAs
indicate that tRNAs having an A36 are expected to have an
N6-isopentenyl modification at A37 (i6A), adjacent to the anti-
FIG. 5. Suppression of nAChR b262UAG mRNA in Xenopus
oocytes. A, normalized dose-response relations for oocytes expressing
wild-type nAChRs. Responses are shown for receptors expressed from
wild type message () or by suppression of the b262UAG message with
either MN3-dCA-Leu (f) or THG73-dCA-Leu (l). Currents have been
normalized to the 400 mM ACh response of each oocyte. Wild type
currents were obtained by injecting a total of 0.1 ng of mRNA with a
2:1:1:1 concentration ratio (a:b:g:d). Suppression of the b262UAG mes-
sage was performed by coinjecting 6 ng of tRNA with 0.63 ng of mRNA
with a 2:1:1:1 concentration ratio (a:b:g:d). B, acetylcholine induced
background currents at position b262UAG as a function of suppressor
tRNA. Oocytes were coinjected with 6 ng of tRNA-dCA and 0.63 ng of
mRNA (2:1:1:1 concentration ratio, a:b:g:d). Currents were recorded at
400 mM ACh.
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codon (27). Of particular relevance here, this modification is
known to be present in the native tRNAGln (CUA) from T.
thermophila and has been shown to increase suppression effi-
ciency in yeast (41). We do not know whether THG73 is modi-
fied after injection by oocyte enzymes; but if not, it is likely that
in vitro, post-transcriptional modification (42, 43) of A37 to i6A
would further increase the suppression efficiency of THG73.
We emphasize that, viewing efficiency from a practical view-
point, the present protocols routinely result in microampere
currents from nAChR. This indicates that the quantity of pro-
tein produced is comparable with that produced in conven-
tional Xenopus heterologous expression studies (although sub-
stantially more mRNA is being injected). Thus, we expect that
unnatural amino acid incorporation can now be applied to the
full range of systems that have been studied with the Xenopus
heterologous expression system.
We anticipate that THG73 will also lead to improved effi-
ciency and fidelity in in vitro studies of unnatural amino acid
incorporation. The in vitro methodology has been used exten-
sively in many systems, and considerable variability in effi-
ciency of incorporation has been noted, including some unnat-
ural residues that lead to no detectable incorporation with the
existing methodology (7). Experiments should be attempted
with THG73 acylated with the more problematical residues.
Lack of Reacylation—A major benefit of THG73 is the essen-
tially complete elimination of receptors that have incorporated
a natural amino acid resulting from acylation of the suppressor
tRNA by an endogenous synthetase. Part of this improvement
arises simply because the increased operational suppression
efficiency allows the injection of severalfold less THG73, so that
the absolute concentration of tRNA available for reacylation is
lower than with MN3. The major improvement, however, de-
rives directly from the diminished interactions with endoge-
nous synthetases.
The tRNA elements recognized by synthetases are typically
located in only a few regions of the tRNA (anticodon, acceptor
stem, and N73), (14–16). As such, nucleotide substitutions de-
signed to decrease productive interactions with the cognate
synthetase might lead to undesired, productive interactions
with one of the other nineteen noncognate synthetases. There-
fore, it was critical to assess whether THG73 was being acyl-
ated by endogenous synthetases. Our results thus far with the
nAChR have revealed no significant complications due to en-
dogenous reacylation of THG73. However, because this meth-
odology will be applied to other proteins and to other heterol-
ogous expression systems, it is worthwhile to explicitly
consider the likelihood of endogenous reacylation of THG73 by
each of the aminoacyl-tRNA synthetases.
Table II summarizes such an analysis. If a residue is known
to produce viable nAChR when inserted at a particular loca-
tion, its cognate synthetase can be rejected on the grounds that
no functional receptors are produced on injection of THG73-
dCA. Mutagenesis studies at a198 and b262 allow a number of
amino acids to be rejected. At a180 the wild type residue is Asp
or Glu in muscle receptors, but in neuronal nAChR, a much
broader range of residues is found. We assume that any resi-
dues that function at this site in the neuronal receptors will
also function in the muscle receptor. This reasoning removes
several other aminoacyl-tRNA synthetases from consideration
(Table II).
A second criterion for eliminating synthetases as potential
candidates for acylation of THG73 is a consideration of rules
that govern tRNA recognition and identity (14–16). With the
exception of the Ala, Ser, and Leu tRNAs, the important rec-
ognition elements for synthetases are typically located in the
anticodon loop (positions 34–36) and/or position 73. Thus, the
synthetases with the greatest likelihood of acylating THG73
would be those that recognize a C34, U35, A36, and/or G73 in the
cognate tRNA. Table II lists the nucleotides found at these
positions in eukaryotic tRNAs for all 20 isoaccepting groups
and the number of overlaps with the corresponding nucleotides
of THG73. As shown in Table II, tRNAs for 12 isoaccepting
groups have either zero or only one nucleotide in common with
THG73 at these positions, indicating that their corresponding
synthetases are unlikely to acylate THG73. Transfer RNAs for
seven isoaccepting groups share two nucleotides in common
with THG73. However, six of the seven synthetases (all but
Gln) can be ruled out based on the AChR viability data.
Based on the synthetase recognition rules and AChR viabil-
ity data, we consider that only two synthetases deserve serious
consideration as potential candidates for acylation of THG73.
First, THG73 possesses C34 and U35, which are known strong
recognition elements for GlnRS, (28, 30), and we have no
nAChR viability data for this amino acid. However, THG73
lacks the G36 and U73 that are likely to be strong recognition
elements for the Xenopus GlnRS (28, 30). Moreover, in vitro
acylation studies show that the native T. thermophila tRNAGln
is not a substrate for GlnRS from either plants (wheat germ)
(13) or mammals (rabbit) (12). We therefore conclude that the
Xenopus GlnRS is unlikely to acylate THG73 under the injec-
tion conditions presently employed.
This leaves LysRS as the only remaining candidate. Like
GlnRS, LysRS can misacylate noncognate tRNAs that possess
CUA anticodons (5). Lys is found in some neuronal nAChR a
subunits at position 180, and we assume that functional recep-
tor would have resulted had Lys been incorporated at 180 in
the muscle-type nAChR studied here. In short, it remains a
formal although unlikely possibility that reacylation by endog-
TABLE II
Analysis of the potential for recognition of THG73 by all
aminoacyl-tRNA synthetases
For the nAChR columns, 3 indicates an amino acid known to function
at the appropriate site in muscle nAChR; n indicates a residue that is
not found in muscle receptors but is found in neuronal nAChR. The
synthetase columns list the nucleotide(s) found at the identified posi-
tion in the appropriate isoaccepting group and the number of positions
in which the residue is compatible with that found in THG73 (No. of
overlaps). The residues found in THG73 are listed at the top of the
columns.
Rejection based on viability in
the nAChR
Rejection based on tRNA/synthetase
recognition rules
Amino
acid a180 a198 b262 G
73 C34 U35 A36 No. ofoverlaps
Ala A N G C 0a
Cys 3 U G C A 1
Asp 3 G G U C 2
Glu 3 A Y U C 2
Phe 3 3 A G A A 1
Gly n A N C C 0
His 3 U-A G U G 1
Ile 3 A (G) A U 0
Lys n G Y U U 3
Leu 3 A N A G
Y A A (1)a
Met A C A U 1
Asn n 3 G G U U 2
Pro C N G G 0
Gln U Y U G 2
Arg n G N C G
Y C U 1
Ser n 3 G N G A
G C U (2)a
Thr n 3 U N G U 0
Val 3 A N A C 0
Trp 3 A C C A 2
Tyr 3 A G U A 2
a For several isoaccepting groups, anticodon recognition is not crucial,
but other key recognition elements are lacking in THG73 (14–16).
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enous LysRS could become a complicating factor in other stud-
ies using TH73G.2
It should be noted that our test for recognition by an endog-
enous synthetase (the observation of functional receptor after
injection of THG73-dCA) is quite stringent. In an actual exper-
iment involving incorporation of an unnatural amino acid, a
THG73-dCA-amino acid is injected; therefore, much less un-
acylated THG73-dCA becomes available for interaction with
endogenous synthetases. Consistent with this argument, MN3-
dCA alone produces currents that are ;60% of those obtained
by injection of MN3-dCA-Tyr at a180 (Table I). However, treat-
ing ACh responses of Fig. 5A as the sum of two components
(one produced by the wild type Leu and the second due to
receptors with another, unknown residue) reveals that,10% of
the total current from injection of MN3-dCA-Leu at b262 is due
to presumed editing or reacylation of MN3-dCA formed from
MN3-dCA-Leu. This suggests that reacylation may be much
less of a problem when a charged tRNA is injected into the
oocyte. Nonetheless, THG73 eliminates even this reacylation,
an important consideration for quantitative experiments.
To summarize, in all cases studied here conditions can be
found under which reacylation/editing by endogenous syn-
thetases is not a complicating factor when THG73 is used. In
other words, in the present system THG73 is functionally “null”
with respect to its amino acid identity in the Xenopus oocyte.
Although it has not been observed here, we acknowledge the
possibility that, in a still more tolerant reporter system, endog-
enous reacylation might become a complicating factor. At pres-
ent, however, the lower limit for detection of functional recep-
tors is at the threshold of the read-through level of UAG codons
inherent in the oocyte’s translation apparatus. Although higher
eukaryotic organisms do not possess conventional UAG-sup-
pressing tRNAs having a CUA anticodon, a low level of read-
through at UAG termination codons has been observed in a
number of these systems (44). This read-through is presumably
produced by “wobble-pairings” involving UAG codons and (a)
the U/CUG anticodons of wild type glutamine tRNAs and/or (b)
the GUA anticodon of tyrosine tRNAs that lack the queuine
modification of the G34 in the anticodon (44).
General Applicability—Our engineered THG73 nonsense-
suppressing tRNA is likely to have broad applicability. Works
in progress in these labs establish that other proteins in addi-
tion to the nAChR can be studied. Also, nonsense suppression
has been observed in mammalian cells (45–47), and since Xe-
nopus and mammalian tRNAs strongly resemble each other, it
seems probable that THG73 will possess a “null” amino acid
identity in somatic cells lines as well. Thus, by combining new
methodologies for introducing macromolecules into somatic cell
lines with the use of our new nonsense-suppressing tRNA
(THG73), it should now be possible to extend the benefits of
unnatural amino acid incorporation to other eukaryotic
systems.
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